Company news

Abeona Therapeutics Inc. (NASDAQ:ABEO) news

Abeona Therapeutics Inc. news releases on 6ix. Latest, Oct 5, 2026: Abeona Therapeutics Announces New Employee Inducement Grants under Nasdaq Listing Rule…

Abeona Therapeutics Inc. (NASDAQ:ABEO) news

Press releases & updates

Abeona Therapeutics Announces New Employee Inducement Grants under Nasdaq Listing Rule 5635(4)

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics® Announces Date of First Quarter Financial Results

Abeona Therapeutics : reg; Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates

Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

Abeona Therapeutics Announces Date of Fourth Quarter, Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

Abeona Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

ABEO: Sells Priority Review Voucher for $155 Million…

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

ABEO: Zevaskyn™ Approved by FDA; Raising Valuation to $11…

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics® Announces Participation in November Investor Conferences